177 related articles for article (PubMed ID: 29666608)
41. Determining Streptococcus suis serotype from short-read whole-genome sequencing data.
Athey TB; Teatero S; Lacouture S; Takamatsu D; Gottschalk M; Fittipaldi N
BMC Microbiol; 2016 Jul; 16(1):162. PubMed ID: 27449127
[TBL] [Abstract][Full Text] [Related]
42. Capsular Polysaccharide Expression in Commensal Streptococcus Species: Genetic and Antigenic Similarities to Streptococcus pneumoniae.
Skov Sørensen UB; Yao K; Yang Y; Tettelin H; Kilian M
mBio; 2016 Nov; 7(6):. PubMed ID: 27935839
[TBL] [Abstract][Full Text] [Related]
43. Sialylation of Streptococcus suis serotype 2 is essential for capsule expression but is not responsible for the main capsular epitope.
Lecours MP; Fittipaldi N; Takamatsu D; Okura M; Segura M; Goyette-Desjardins G; Van Calsteren MR; Gottschalk M
Microbes Infect; 2012 Sep; 14(11):941-50. PubMed ID: 22521569
[TBL] [Abstract][Full Text] [Related]
44. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
[TBL] [Abstract][Full Text] [Related]
45. Colloidal gold-based immunochromatographic strip test compromising optimised combinations of anti-S. suis capsular polysaccharide polyclonal antibodies for detection of Streptococcus suis.
Nakayama T; Zhao J; Takeuchi D; Kerdsin A; Chiranairadul P; Areeratana P; Loetthong P; Pienpringam A; Akeda Y; Oishi K
Biosens Bioelectron; 2014 Oct; 60():175-9. PubMed ID: 24800681
[TBL] [Abstract][Full Text] [Related]
46. Dual actions of group B
Uchiyama S; Sun J; Fukahori K; Ando N; Wu M; Schwarz F; Siddiqui SS; Varki A; Marth JD; Nizet V
Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7465-7470. PubMed ID: 30910970
[TBL] [Abstract][Full Text] [Related]
47. Role of capsular sialic acid in virulence and resistance to phagocytosis of Streptococcus suis capsular type 2.
Charland N; Kobisch M; Martineau-Doizé B; Jacques M; Gottschalk M
FEMS Immunol Med Microbiol; 1996 Jul; 14(4):195-203. PubMed ID: 8856318
[TBL] [Abstract][Full Text] [Related]
48. [Cloning and analysis of the conserved regions in the capsular polysaccharides synthesis locus of Streptococcus suis].
Wang K; Lu C; Fan W
Wei Sheng Wu Xue Bao; 2012 May; 52(5):573-80. PubMed ID: 22803342
[TBL] [Abstract][Full Text] [Related]
49. Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.
Goyette-Desjardins G; Calzas C; Shiao TC; Neubauer A; Kempker J; Roy R; Gottschalk M; Segura M
Infect Immun; 2016 Jul; 84(7):2059-2075. PubMed ID: 27113360
[TBL] [Abstract][Full Text] [Related]
50. Streptococcus suis capsular polysaccharide inhibits phagocytosis through destabilization of lipid microdomains and prevents lactosylceramide-dependent recognition.
Houde M; Gottschalk M; Gagnon F; Van Calsteren MR; Segura M
Infect Immun; 2012 Feb; 80(2):506-17. PubMed ID: 22124659
[TBL] [Abstract][Full Text] [Related]
51. Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide.
Paoletti LC; Ross RA; Johnson KD
Infect Immun; 1996 Apr; 64(4):1220-6. PubMed ID: 8606082
[TBL] [Abstract][Full Text] [Related]
52. TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness.
Graveline R; Segura M; Radzioch D; Gottschalk M
Int Immunol; 2007 Apr; 19(4):375-89. PubMed ID: 17307800
[TBL] [Abstract][Full Text] [Related]
53. Streptococcus suis and group B Streptococcus differ in their interactions with murine macrophages.
Segura MA; Cléroux P; Gottschalk M
FEMS Immunol Med Microbiol; 1998 Jul; 21(3):189-95. PubMed ID: 9718208
[TBL] [Abstract][Full Text] [Related]
54. Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes.
Carlin AF; Lewis AL; Varki A; Nizet V
J Bacteriol; 2007 Feb; 189(4):1231-7. PubMed ID: 16997964
[TBL] [Abstract][Full Text] [Related]
55. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
56. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide.
Wessels MR; Benedí WJ; Jennings HJ; Michon F; DiFabio JL; Kasper DL
Infect Immun; 1989 Apr; 57(4):1089-94. PubMed ID: 2494110
[TBL] [Abstract][Full Text] [Related]
57. Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci.
Aoyagi Y; Adderson EE; Min JG; Matsushita M; Fujita T; Takahashi S; Okuwaki Y; Bohnsack JF
J Immunol; 2005 Jan; 174(1):418-25. PubMed ID: 15611266
[TBL] [Abstract][Full Text] [Related]
58. Potentially hazardous Streptococcus suis strains latent in asymptomatic pigs in a major swine production area of Thailand.
Meekhanon N; Kaewmongkol S; Phimpraphai W; Okura M; Osaki M; Sekizaki T; Takamatsu D
J Med Microbiol; 2017 May; 66(5):662-669. PubMed ID: 28516843
[TBL] [Abstract][Full Text] [Related]
59. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
60. Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development.
Bellais S; Six A; Fouet A; Longo M; Dmytruk N; Glaser P; Trieu-Cuot P; Poyart C
J Infect Dis; 2012 Dec; 206(11):1745-52. PubMed ID: 23002446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
